PT  - JOURNAL ARTICLE
AU  - Randy L. Bell
AU  - Richard R. Harris
AU  - Peter E. Malo
AU  - Jennifer B. Bouska
AU  - Thomas K. Shaughnessy
AU  - Keren I. Hulkower
AU  - Clint D. W. Brooks
AU  - George W. Carter
TI  - ABT-761 Attenuates Bronchoconstriction and Pulmonary Inflammation in Rodents
DP  - 1997 Mar 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 1366--1373
VI  - 280
IP  - 3
4099  - http://jpet.aspetjournals.org/content/280/3/1366.short
4100  - http://jpet.aspetjournals.org/content/280/3/1366.full
SO  - J Pharmacol Exp Ther1997 Mar 01; 280
AB  - Our primary goal has been to discover leukotriene biosynthesis inhibitors with characteristics that are appropriate for use as clinical agents. The success of the use of zileuton in the treatment of asthma led us to explore further the use of theN-hydroxyurea class of 5-lipoxygenase inhibitors as longer-acting compounds with good lung penetration. A variety ofin vitro and in vivo methods were used to evaluate a large number of compounds, from which ABT-761 [(R)-N-(3-(5-(4-fluorophenylmethyl)thien-2-yl)-1-methyl-2-propynyl)-N-hydroxyurea] was selected for study. ABT-761 exhibited potent and selective inhibition of leukotriene formation both in vitro andin vivo. More importantly, the compound potently inhibited antigen-induced bronchospasm in guinea pigs when given either prophylactically or therapeutically. In addition, ABT-761 was a potent inhibitor of eosinophil influx into the lungs of Brown Norway rats. These data provide added support for the role of leukotrienes in both bronchospasm and eosinophilic inflammation and characterize ABT-761 as a particularly potent inhibitor of leukotrienes formed in pulmonary tissues. These data combined with the excellent pharmacokinetic characteristics of the compound indicate its potential use in the treatment of leukotriene-dependent human disease. The American Society for Pharmacology and Experimental Therapeutics